IN2014MN01887A - - Google Patents

Info

Publication number
IN2014MN01887A
IN2014MN01887A IN1887MUN2014A IN2014MN01887A IN 2014MN01887 A IN2014MN01887 A IN 2014MN01887A IN 1887MUN2014 A IN1887MUN2014 A IN 1887MUN2014A IN 2014MN01887 A IN2014MN01887 A IN 2014MN01887A
Authority
IN
India
Prior art keywords
treatment
prevention
hsp60
suppression
diapep277
Prior art date
Application number
Inventor
Irun R Cohen
Raanan Margalit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IN2014MN01887A publication Critical patent/IN2014MN01887A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60) and for suppression prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™ a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression prevention or treatment of T2D.
IN1887MUN2014 2012-03-01 2013-02-28 IN2014MN01887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605262P 2012-03-01 2012-03-01
PCT/IL2013/050174 WO2013128450A1 (en) 2012-03-01 2013-02-28 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Publications (1)

Publication Number Publication Date
IN2014MN01887A true IN2014MN01887A (en) 2015-07-10

Family

ID=48050870

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1887MUN2014 IN2014MN01887A (en) 2012-03-01 2013-02-28

Country Status (8)

Country Link
US (1) US20150018271A1 (en)
EP (1) EP2819692A1 (en)
JP (1) JP2015508812A (en)
CN (1) CN104244967A (en)
AU (1) AU2013227249A1 (en)
CA (1) CA2864655A1 (en)
IN (1) IN2014MN01887A (en)
WO (1) WO2013128450A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4061832A4 (en) * 2019-11-18 2024-05-29 The Methodist Hospital System Nanovaccine for heart failure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5578303A (en) 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5780034A (en) 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
PT820303E (en) 1994-12-21 2003-10-31 Yeda Res & Dev ANALYSIS OF P277 PEPTIDE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
IL114407A0 (en) 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
WO2003070761A1 (en) 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
EP1718158B1 (en) * 2004-01-28 2014-07-02 Andromeda Bio Tech Ltd. Hsp therapy in conjunction with a low antigenicity diet
KR20050104152A (en) 2004-04-28 2005-11-02 최승호 Enhancing systems for poorly absorptive drugs
US20070128193A1 (en) * 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
US20150018271A1 (en) 2015-01-15
WO2013128450A1 (en) 2013-09-06
EP2819692A1 (en) 2015-01-07
CA2864655A1 (en) 2013-09-06
JP2015508812A (en) 2015-03-23
AU2013227249A1 (en) 2014-09-11
CN104244967A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
ZA201705113B (en) Cysteine protease
MX2017010389A (en) Cysteine protease.
MX2021006017A (en) Methods and compositions for treatment of disorders with follistatin polypeptides.
MX368373B (en) Co rti statin analogues for the treatment of inflammatory and/or immune diseases.
MX2017009595A (en) Anti-senescence compounds and uses thereof.
MX2012009748A (en) Use of transforming growth factor - beta 1 (tgf-î²1) inhibitor peptides for the treatment of corneal fibrosis and/or haze.
MX2016010951A (en) Multimeric fc proteins.
IN2014CN04498A (en)
MX2013012791A (en) Complement factor b analogs and their uses.
MX2015005252A (en) Novel method for treating cardiac infarction using hmgb1 fragment.
ZA201905851B (en) Peptides and methods for the treatment of diabetes
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
GB201118201D0 (en) Novel peptides
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
SG10201805039UA (en) Protease resistant peptides
EP3292286A4 (en) System to control and condition the supply of natural gas to bi-fuel engines
SG11202000801QA (en) Highly versatile method of presenting cyclic peptide on protein structure
PH12015501870B1 (en) Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof
IL270199A (en) Peptides for treatment of diabetes
MX2019003970A (en) Immunogenic arginase peptides.
MX2016000448A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
MX362058B (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis